Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6 …
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
Tremfya - cloud.e.janssen.com
We look forward to sharing more with you about TREMFYA ® (guselkumab). In the meantime, if you have any questions, feel free to call a Janssen CarePath Care Coordinator at …
TREMFYA® - cloud.e.janssen.com
TREMFYA® is a prescription medicine used to treat adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with moderate to severe plaque psoriasis who may …
Janssen Presents Results of First Head-to-Head Study of Biologic ...
Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn’s Disease
Janssen Submits Supplemental New Drug Application to U.S. FDA …
Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with …
Press Releases | Janssen
Month -Month Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year -Year 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 NO RESULTS FOUND
Products - Janssen
Find product information for the medicines offered by Janssen and search for specific medications based upon therapeutic area or country.
twitter-disclaimer | Janssen Norway
Janssen-Cilags Twitter-konto /JanssenNorge er rettet mot norske lesere, og innleggene er skrevet av det digitale teamet, samt kommunikasjonsavdelingen i Janssen-Cilag.
Janssen Submits Applications in U.S. and EU Seeking Approval of ...
Janssen Submits Applications in U.S. and EU Seeking Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)/ DARZALEX® (daratumumab) Subcutaneous (SC) …
Blogs | Janssen
Featured Blogs ONCOLOGY Progress, Patients & Passion: Reflections on World Cancer Day 2019 Jeffrey R. Infante, M.D. Vice President Early Development, Oncology Janssen Research …